Usefulness of the serum carcinoembryonic antigen kinetic for chemotherapy monitoring in patients with unresectable metastasis of colorectal cancer

Journal of Clinical Oncology

Volumn 26, Issue 22, 2008, Pages 3681-3686

  Iwanicki Caron, Isabelle ^a   Di Fiore, Frédéric ^a   Roque, Isabelle ^a   Astruc, Emilie ^a   Stetiu, Monica ^a   Duclos, Aude ^a   Tougeron, David ^a   Saillard, Sandrine ^a   Thureau, Sébastien ^a   Benichou, Jacques ^a   Paillot, Bernard ^a   Basuyau, Jean Pierre ^a   Michel, Pierre ^a  

^a ROUEN UNIVERSITY HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CARCINOEMBRYONIC ANTIGEN; FLUOROPYRIMIDINE; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; OXALIPLATIN; ANTINEOPLASTIC AGENT;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; CALCULATION; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER SURVIVAL; CLINICAL TRIAL; COLORECTAL CANCER; CONTROLLED STUDY; CORRELATION ANALYSIS; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; DISEASE COURSE; FEMALE; HAZARD RATIO; HUMAN; HUMAN TISSUE; KAPLAN MEIER METHOD; KINETICS; LIVER METASTASIS; LUNG METASTASIS; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; PATIENT MONITORING; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; RECEIVER OPERATING CHARACTERISTIC; RISK; TREATMENT RESPONSE; BLOOD; COLORECTAL TUMOR; DISEASE FREE SURVIVAL; DRUG MONITORING; IMMUNOLOGY; LIVER TUMOR; LUNG TUMOR; METASTASIS; METHODOLOGY; MIDDLE AGED; PATHOLOGY; PREDICTION AND FORECASTING; PROSPECTIVE STUDY; ROC CURVE; SENSITIVITY AND SPECIFICITY; TREATMENT OUTCOME;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; CARCINOEMBRYONIC ANTIGEN; COLORECTAL NEOPLASMS; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; DRUG MONITORING; FEMALE; HUMANS; KAPLAN-MEIERS ESTIMATE; KINETICS; LIVER NEOPLASMS; LUNG NEOPLASMS; MALE; MIDDLE AGED; ODDS RATIO; PREDICTIVE VALUE OF TESTS; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; ROC CURVE; SENSITIVITY AND SPECIFICITY; TREATMENT OUTCOME;

EID: 49249085578     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2007.15.0904     Document Type: Article

References (21)

1. Meyerhardt JA, Mayer RJ: Systemic therapy for colorectal cancer. N Engl J Med 352:476-487, 2005
2. Jemal A, Murray T, Ward, et al: Cancer statistics. CA Cancer J Clin 55:10-30, 2005
3. Jaffe CC: Measures of response: RECIST, WHO, and new alternatives. J Clin Oncol 24:3245-3251, 2006
4. Locker GY, Hamilton S, Harris J, et al: ASCO 2006 update of recommendations for the use of tumor markers in gastrointestinal cancer. J Clin Oncol 24:5313-5327, 2006
5. Holt AD, Kim JT, Murrel Z, et al: The role of carcinoembryonic antigen as a predictor of the need for preoperative computed tomography in colon cancer patients. Am Surg 72:897-901, 2006
6. Mayer RJ, Garnick MB, Steele GD Jr, et al: Carcinoembryonic antigen (CEA) as a monitor of chemotherapy in disseminated colorectal cancer. Cancer 42:1428-1433, 1978 (suppl 3)
7. Shani A, O'Connell MJ, Moertel CG, et al: Serial plasma carcinoembryonic antigen measurements in the management of metastatic colorectal carcinoma. Ann Intern Med 88:627-630, 1978
8. Allen-Mersh TG, Kemeny N, Niedzwiecki D, et al: Significance of a fall in serum CEA concentration in patients treated with cytotoxic chemotherapy for disseminated colorectal cancer. Gut 28:1625-1629, 1987
9. Ward U, Primrose JN, Finan PJ, et al: The use of tumour markers CEA, CA-195 and CA-242 in evaluating the response to chemotherapy in patients with advanced colorectal cancer. Br J Cancer 67:1132-1135, 1993
10. Tsavaris N, Vonorta K, Tsoutsos H, et al: Carcinoembryonic antigen (CEA), alpha-fetoprotein, CA 19.9 and CA 125 in advanced colorectal cancer (ACC). Int J Biol Markers 8:88-93, 1993
11. Hanke B, Riedel C, Lampert S, et al: CEA and CA 19-9 measurement as a monitoring parameter in metastatic colorectal cancer (CRC) under palliative first-line chemotherapy with weekly 24-hour infusion of high-dose 5-fluorouracil (5-FU) and folinic acid (FA). Ann Oncol 12:221-226, 2001
12. Wang WS, Lin JK, Lin TC, et al: Tumor marker CEA in monitoring of response to tegafururacil and folinic acid in patients with metastatic colorectal cancer. Hepatogastroenterology 49:388-392, 2002
13. Trillet-Lenoir V, Chapuis F, Touzet S, et al: Any clinical benefit from the use of oncofoetal markers in the management of chemotherapy for patients with metastatic colorectal carcinomas? Clin Oncol (R Coll Radiol) 16:196-203, 2004
14. Riedinger JM, Wafflart J, Ricolleau G, et al: CA125 half-life and CA125 nadir during induction chemotherapy are independent predictors of epithelial ovarian cancer outcome: Results of a French multicentric study. Ann Oncol 17:1234-1238, 2006
15. Bidart JM, Thuillier F, Augereau C, et al: Kinetics of serum tumor marker concentrations and usefulness in clinical monitoring. Clin Chem 45:1695-1707, 1999
16. Therasse P, Susan G, Arbuck SG, et al: New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 92:205-216, 2000
17. Buyse M, Burzykowski T, Carroll K, et al: Progression-free survival is a surrogate for survival in advanced colorectal cancer. J Clin Oncol 25:5218-5224, 2007
18. Dimitrakopoulou-Strauss A, Strauss LG, Dimitri J: PET-FDG as predictor of therapy response in patients with colorectal carcinoma. Q J Nucl Med 47:8-13, 2003
19. Tang PA, Bentzen SM, Chen EX, et al: Surrogate end points for median overall survival in metastatic colorectal cancer: Literature-based analysis from 39 randomized controlled trials of first-line chemotherapy. J Clin Oncol 25:4562-4568, 2007
20. Wang J-Y, Hsieh J-S, Chang M-Y, et al: Molecular detection of APC, K-ras, and p53 mutations in the serum of colorectal cancer patients as circulating biomarkers. World J Surg 28:721-726, 2004
21. Meropol NJ, Cohen SJ, Iannotti N, et al: Circulating tumor cells (CTC) predict progression free (PFS) and overall survival (OS) in patients with metastatic colorectal cancer. J Clin Oncol 25:18S, 2007 (suppl, abstr 4010)